Literature DB >> 31207605

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.

Francesca Alfei1, Kristiyan Kanev1, Maike Hofmann2, Ming Wu1, Hazem E Ghoneim3,4, Patrick Roelli1,5,6, Daniel T Utzschneider7, Madlaina von Hoesslin1, Jolie G Cullen1, Yiping Fan8, Vasyl Eisenberg9, Dirk Wohlleber10, Katja Steiger11, Doron Merkler12, Mauro Delorenzi5,6, Percy A Knolle10, Cyrille J Cohen9, Robert Thimme13, Benjamin Youngblood14, Dietmar Zehn15.   

Abstract

Cytotoxic T cells are essential mediators of protective immunity to viral infection and malignant tumours and are a key target of immunotherapy approaches. However, prolonged exposure to cognate antigens often attenuates the effector capacity of T cells and limits their therapeutic potential1-4. This process, known as T cell exhaustion or dysfunction1, is manifested by epigenetically enforced changes in gene regulation that reduce the expression of cytokines and effector molecules and upregulate the expression of inhibitory receptors such as programmed cell-death 1 (PD-1)5-8. The underlying molecular mechanisms that induce and stabilize the phenotypic and functional features of exhausted T cells remain poorly understood9-12. Here we report that the development and maintenance of populations of exhausted T cells in mice requires the thymocyte selection-associated high mobility group box (TOX) protein13-15. TOX is induced by high antigen stimulation of the T cell receptor and correlates with the presence of an exhausted phenotype during chronic infections with lymphocytic choriomeningitis virus in mice and hepatitis C virus in humans. Removal of its DNA-binding domain reduces the expression of PD-1 at the mRNA and protein level, augments the production of cytokines and results in a more polyfunctional T cell phenotype. T cells with this deletion initially mediate increased effector function and cause more severe immunopathology, but ultimately undergo a massive decline in their quantity, notably among the subset of TCF-1+ self-renewing T cells. Altogether, we show that TOX is a critical factor for the normal progression of T cell dysfunction and the maintenance of exhausted T cells during chronic infection, and provide a link between the suppression of effector function intrinsic to CD8 T cells and protection against immunopathology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31207605     DOI: 10.1038/s41586-019-1326-9

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1 in total

1.  V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition.

Authors:  S R Dillon; S C Jameson; P J Fink
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

  1 in total
  202 in total

Review 1.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

2.  Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.

Authors:  Nathan Singh; Yong Gu Lee; Saar Gill; Marco Ruella; Olga Shestova; Pranali Ravikumar; Katharina E Hayer; Seok Jae Hong; Xueqing Maggie Lu; Raymone Pajarillo; Sangya Agarwal; Shunichiro Kuramitsu; Elena J Orlando; Karen Thudium Mueller; Charly R Good; Shelley L Berger; Ophir Shalem; Matthew D Weitzman; Noelle V Frey; Shannon L Maude; Stephan A Grupp; Carl H June
Journal:  Cancer Discov       Date:  2020-01-30       Impact factor: 39.397

Review 3.  CD8+ T cell states in human cancer: insights from single-cell analysis.

Authors:  Anne M van der Leun; Daniela S Thommen; Ton N Schumacher
Journal:  Nat Rev Cancer       Date:  2020-02-05       Impact factor: 60.716

Review 4.  Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey.

Authors:  Mohamed A ElTanbouly; Randolph J Noelle
Journal:  Nat Rev Immunol       Date:  2020-10-19       Impact factor: 53.106

5.  Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice.

Authors:  Hao Hu; Pavel N Zakharov; Orion J Peterson; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

6.  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.

Authors:  Qiaohong Wang; Jingze Gao; Wen Di; Xia Wu
Journal:  Cancer Immunol Immunother       Date:  2020-04-28       Impact factor: 6.968

Review 7.  Defining 'T cell exhaustion'.

Authors:  Christian U Blank; W Nicholas Haining; Werner Held; Patrick G Hogan; Axel Kallies; Enrico Lugli; Rachel C Lynn; Mary Philip; Anjana Rao; Nicholas P Restifo; Andrea Schietinger; Ton N Schumacher; Pamela L Schwartzberg; Arlene H Sharpe; Daniel E Speiser; E John Wherry; Benjamin A Youngblood; Dietmar Zehn
Journal:  Nat Rev Immunol       Date:  2019-09-30       Impact factor: 53.106

8.  Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion.

Authors:  Ansuman T Satpathy; Jeffrey M Granja; Kathryn E Yost; Yanyan Qi; Francesca Meschi; Geoffrey P McDermott; Brett N Olsen; Maxwell R Mumbach; Sarah E Pierce; M Ryan Corces; Preyas Shah; Jason C Bell; Darisha Jhutty; Corey M Nemec; Jean Wang; Li Wang; Yifeng Yin; Paul G Giresi; Anne Lynn S Chang; Grace X Y Zheng; William J Greenleaf; Howard Y Chang
Journal:  Nat Biotechnol       Date:  2019-08-02       Impact factor: 54.908

9.  Early precursor T cells establish and propagate T cell exhaustion in chronic infection.

Authors:  Daniel T Utzschneider; Sarah S Gabriel; David Chisanga; Renee Gloury; Patrick M Gubser; Ajithkumar Vasanthakumar; Wei Shi; Axel Kallies
Journal:  Nat Immunol       Date:  2020-08-24       Impact factor: 25.606

10.  Expression pattern, regulation, and clinical significance of TOX in breast cancer.

Authors:  Mohit Arora; Sarita Kumari; Jay Singh; Anita Chopra; Shyam S Chauhan
Journal:  Cancer Immunol Immunother       Date:  2020-08-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.